A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Terminated · Phase 1 · NCT05121103
Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
At a glance
- Research payments reported, 2025
- $102,732
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 13
About the trial
- Sponsor
- Epizyme, Inc.
- Tested
- EZM0414 (drug)
- Dates
- Started 2022-05-31; completion 2024-04-30
- Results posted
- Yes
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). DLBCL is also a type of cancer of the blood. They are referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. The study has 2 main parts, called phase 1 and phase 1b. The main objective of both parts will be to evaluate the safety and tolerability of the study drug, called EZM0414. The main objective of phase 1b will also be to determine the effectiveness of EZM0414. During phase 1 six do…
From ClinicalTrials.gov, last updated 2025-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $102,732 in research payments for this study in 2025 (35 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Iuliana Shapira, MD Hematology & Oncology · Little Silver, NJ
- Neha Korde, MD Internal Medicine · New York, NY
- Ruben Niesvizky, MD Hematology & Oncology · New York, NY
- Joshua R. Richter, M.D. Medical Oncology · New York, NY
- Dai Chihara, MD, PHD Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Cornell Medicine $65,053
- Mount Sinai Hospital $20,729
- Ut MD Anderson Cancer Center $9,321
- Maryland Oncology Hematology Chevy Chase $4,743
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $2,886
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.